Markets

Verastem Oncology To Present Data From New Molecular Profiling, Tumor Biomarker Analysis Of Phase 2 RAMP 201 Clinical Trial Of Avutometinib Plus Defactinib In Patients With Recurrent LGSOC, At IGCS 2026

Oct 2, 2026 · 07:32 AM ET· updated 2h ago

RAMP 201 molecular profiling showed clinically meaningful activity in KRAS wild-type recurrent LGSOC, including ORRs of 22% in patients with NRAS- or BRAF-mutated tumors and 18% in patients with KRAS/NRAS/BRAF triple

Why It Matters

Verastem tested a cancer drug combination on a specific tumor type. The treatment showed some patients' tumors shrank, which helps doctors understand if the drug might work.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

VSTM7.89

-0.01 (-0.10%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.